Windtree Therapeutics, Inc. Return on Tangible Assets

Return on Tangible Assets of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Return on Tangible Assets growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Return on Tangible Assets for 2019 was -163.13% (a -72.67% decrease from previous year)
  • Annual Return on Tangible Assets for 2018 was -596.98% (a -307.8% decrease from previous year)
  • Annual Return on Tangible Assets for 2017 was 287.29% (a -62.58% decrease from previous year)
  • Twelve month Return on Tangible Assets ending June 29, 2020 was -138.24% (a -40.04% decrease compared to previous quarter)
  • Twelve month trailing Return on Tangible Assets decreased by -132.32% year-over-year
Trailing Return on Tangible Assets for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
-138.24% -230.57% -163.13% 427.75%
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Return on Tangible Assets of Windtree Therapeutics, Inc.

Most recent Return on Tangible Assetsof WINT including historical data for past 10 years.

Interactive Chart of Return on Tangible Assets of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Return on Tangible Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 -163.13%
2018 -596.98%
2017 287.29%
2016 767.84%
2015 -179.33%
2014 -111.92%
2013 -58.69%
2012 -209.12%
2011 -1179.8%
2010 -300.22%

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.